Sharekhan

Hester Biosciences Ltd

Thu 13/03/2025,15:53:17 | NSE : HESTERBIO

₹ 1352.4071.25 (5.56%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1287.60

Previous Close

₹ 1281.15

Volume

26468

Mkt Cap ( Rs. Cr)

₹1150.47

High

₹ 1378.25

Low

₹ 1275.00

52 Week High

₹ 3379.00

52 Week Low

₹ 1252.70

Book Value Per Share

₹ 354.81

Dividend Yield

0.44

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Hester Biosciences Ltd

Your Vote -

Buy

88.89%

Hold

2.78%

Sell

8.33%

88.89%

36 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

1352.40

42

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

42

Option Chain

Analyzes market sentiment, predicts Hester Biosciences Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Hester Biosciences L - Intimation Of Shifting Of The Registered Office Of The Company

    18 Feb 2025, 1:34PM Intimation of shifting of the Registered Office of the Company with effect from 13 February 2025
  • Hester Biosciences L - Address Change

    18 Feb 2025, 1:34PM Hester Biosciences Limited has informed the Exchange regarding change in Registered Office of the company.
  • Hester Biosciences L - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report

    14 Feb 2025, 2:54PM Postal Ballot Voting result and scrutiniser report
  • Hester Biosciences L - Shareholders meeting

    14 Feb 2025, 2:53PM Hester Biosciences Limited has informed the Exchange regarding Proceedings of Postal Ballot. Further, the company has informed the Exchange regarding
  • Hester Biosciences L - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

    14 Feb 2025, 2:51PM Outcome - Proceedings and Voting Results of Postal Ballot Process to get approval of Members on resolution mentioned in Postal Ballot Notice dated 8 J
  • Hester Biosciences L - Integrated Filing- Governance

    8 Feb 2025, 10:47AM Integrated Filing (Governance) for the quarter ended 31 December 2024
  • Hester Biosciences L - Integrated Filing (Governance) For The Quarter Ended 31 December 2024

    8 Feb 2025, 10:49AM Integrated Filling (Governance) for the quarter ended 31 December 2024
  • Hester Biosciences L - Analysts/Institutional Investor Meet/Con. Call Updates

    1 Feb 2025, 6:29PM Hester Biosciences Limited has informed the Exchange about Transcript
  • Hester Biosciences L - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    1 Feb 2025, 6:27PM Transcript of Earnings Conference Call held on 30 January 2025 at 2:00 p.m. IST.
  • Hester Biosciences L - Copy of Newspaper Publication

    31 Jan 2025, 1:02PM Hester Biosciences Limited has informed the Exchange about Copy of Newspaper Publication
  • Hester Biosciences L - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    30 Jan 2025, 3:43PM Audio recording of the Earnings Conference Call held on 30 January 2025
  • Hester Biosciences L - Analysts/Institutional Investor Meet/Con. Call Updates

    30 Jan 2025, 3:43PM Hester Biosciences Limited has informed the Exchange about Link of Recording
  • Hester Biosciences L - Integrated Filing- Financial

    30 Jan 2025, 12:35PM 20241231 Q3 & 9M FY25 Results
  • Hester Biosciences L - Press Release

    30 Jan 2025, 12:20PM Hester Biosciences Limited has informed the Exchange regarding a press release dated January 30, 2025, titled ""20250130 Q3 & 9M FY25 Press Release"".
  • Hester Biosciences L - Financial Result Updates

    30 Jan 2025, 12:10PM Hester Biosciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
  • Hester Biosciences L - Outcome of Board Meeting

    30 Jan 2025, 12:07PM Hester Biosciences Limited has informed the Exchange regarding Board meeting held on January 30, 2025.
  • Hester Biosciences L Q3 net profit down 31.48% at Rs 4.44 cr

    30 Jan 2025, 1:50PM The company reported standalone net profit of Rs 4.44 crore for the quarter ended December 31, 2024 as compared to Rs 6.48 crore in the same period la
  • Hester Biosciences L - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    30 Jan 2025, 12:23PM 20250130 Q3 & 9M FY25 Press Release
  • Hester Biosciences L - Integrated Filing (Financial)

    30 Jan 2025, 12:13PM Integrated filling of financial results for the quarter and nine months period ended 31 December 2024
  • Hester Biosciences L - Board Meeting Outcome for Outcome Of Board Meeting Held On 30 Janauary 2025

    30 Jan 2025, 12:06PM Outcome of Board Meeting held on 30 January 2025
  • Hester Biosciences L - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    23 Jan 2025, 2:06PM Intimation of earnings conference call through teleconference call on Thursday, 30 January 2025 at 2:00 p.m. (IST), post the announcement of financial
  • Hester Biosciences L - Analysts/Institutional Investor Meet/Con. Call Updates

    23 Jan 2025, 2:06PM Hester Biosciences Limited has informed the Exchange about Schedule of meet
  • Hester Biosciences L - Board Meeting Intimation

    22 Jan 2025, 3:28PM HESTER BIOSCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 30-Jan-2025 to inter-alia consider and approve the Unaudited Fi
  • Hester Biosciences L - Board Meeting Intimation for Financial Results

    22 Jan 2025, 3:27PM HESTER BIOSCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2025 ,inter alia, to consider
  • Hester Biosciences L - Action(s) initiated or orders passed

    21 Jan 2025, 5:05PM Hester Biosciences Limited has informed the Exchange about order passed by GST Department, Panchkula, Haryana
  • Hester Biosciences L - Intimation Regarding Receipt Of Order From GST Department, Panchkula (Haryana)

    21 Jan 2025, 5:14PM Disclosure with respect to the order passed by GST Department, Panchkula, Haryana for Branch transactions for the FY2017-18 to FY2020-21.
  • Hester Biosciences L - Copy of Newspaper Publication

    14 Jan 2025, 9:10AM Hester Biosciences Limited has informed the Exchange about Copy of Newspaper Publication
  • Hester Biosciences L - Notice Of Shareholders Meetings-XBRL

    13 Jan 2025, 12:30PM HESTER BIOSCIENCES LIMITED has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot
  • Hester Biosciences L - Shareholders meeting

    13 Jan 2025, 12:27PM Hester Biosciences Limited has informed the Exchange regarding Notice of Postal Ballot
  • Hester Biosciences L has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024

    9 Jan 2025, 5:50PM As of December 2024, 53.73% is owned by Promoters and 46.27% by Public. <p align=justify> Among Promoters holding, Indian Promoters holds 44.28% and F
  • Hester Biosciences L - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    9 Jan 2025, 2:35PM Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31 December 2024.
  • Hester Biosciences L - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    9 Jan 2025, 2:33PM Hester Biosciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Hester Biosciences L - Updates

    8 Jan 2025, 4:34PM Hester Biosciences Limited has informed the Exchange regarding 'Outcome of Resolution Passed by the Board of Directors by Circulation'.
  • Hester Biosciences L - Outcome Of Resolutions Passed By The Board Of Directors By Circulation

    8 Jan 2025, 4:34PM Outcome of Resolution passed by the Board of Directors By Circulation has approved the shifting of Registered Office of the Company.
  • Hester Biosciences L - Updates

    6 Jan 2025, 10:05AM Hester Biosciences Limited has informed the Exchange regarding 'Change of name of Registrar and Share Transfer Agent (""RTA"") of the Company'.
  • Hester Biosciences L - Change Of Name Of Registrar And Share Transfer Agent (\RTA\) Of The Company

    6 Jan 2025, 10:05AM Change of Name of Registrar and Share Transfer Agent (RTA) from Link Intime India Private Limited to \MUFG Intime India Private Limited\ with effect f
  • Hester Biosciences L - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    24 Dec 2024, 2:52PM HESTER BIOSCIENCES LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer
  • Hester Biosciences L - Resignation

    24 Dec 2024, 2:46PM Hester Biosciences Limited has informed the Exchange regarding Resignation of Dr. Ram Prakash as Chief Operating Officer (COO) of the company w.e.f.
  • Hester Biosciences L - Announcement under Regulation 30 (LODR)-Change in Management

    24 Dec 2024, 2:46PM Pursuant to regulation 30 of Listing Regulations, we hereby inform that Dr. Ram Prakash, Chief Operating Officer (COO) (categorised as Senior Manageme
  • Hester Biosciences L - Trading Window-XBRL

    23 Dec 2024, 2:40PM HESTER BIOSCIENCES LIMITED has informed the Exchange about Closure of Trading Window
  • Hester Biosciences L - Trading Window

    23 Dec 2024, 2:39PM Hester Biosciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulation
  • Hester Biosciences L - Credit Rating

    20 Dec 2024, 12:24PM Hester Biosciences Limited has informed the Exchange about Credit Rating
  • Hester Biosciences L - Announcement under Regulation 30 (LODR)-Credit Rating

    20 Dec 2024, 12:24PM Intimation of assigned/ re-affirmed credit ratings on Long-term and Short-term credit facilities availed by the Company by CARE Ratings Limited vide i
  • Hester Biosciences

    29 Dec 2022 , 10:49AM Hester Biosciences Ltd will develop and commercialize the low pathogenic avian influenza inactivated vaccine for poultry as the company has signed an agreement to acquire the indigenously developed technology from Indian Council of Agricultural Research - National Institute of High Security Animal Diseases (ICAR-NIHSAD), for the development and commercialization of the Low Pathogenic Avian Influenza (H9N2 strain) Inactivated Vaccine for poultry. Hester has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals. Besides supplying the vaccine within India, Hester intends to export this vaccine to African and Asian countries through its own distribution network, where the demand for this vaccine has already been established. Our view: It’s a positive read through for the stock
  • Hester acquires technology from ICAR – NIHSAD

    28 Dec 2022 , 11:36AM Hester acquires technology from ICAR – NIHSAD to develop a Low Pathogenic Avian Influenza (H9N2 strain) Inactivated Vaccine for poultry
  • Hester Biosciences gets Rs. 600 million grant to make COVID vaccine

    8 Apr 2022 , 1:46PM Board approves the execution of Grantin-Aid Letter Agreement for grant of Rs. 600 million
  • Hester Biosciences forays into Pet Care sector with New Products

    22 Mar 2022 , 1:58PM Hester Biosciences will expand into the rapidly growing Pet Care sector this April
  • Hester Biosciences

    30 Dec 2021 , 11:36AM To commence supplies of drug substance for Bharat Biotech’s Covid-19 vaccine Covaxin by April 2022. The company is constructing a biosafety level -3 facility at its Mehsana plant with an investment of Rs 100, which will enable it to produce 5-7 million doses of the Covaxin drug substance every month. Earlier in May 2021 Hester has entered in to an agreement with Bharat Biotech to make drug substance for Covaxin. As per the agreement, Hester will supply the drug substance to Bharat Biotech which will then do the fill-finish at its facilities. Positive read thru
  • Cadila, Hester Biosceinces

    27 Dec 2021 , 1:27PM The Government of India has announced the commencement of the vaccination for children in the age group of 15-18 years. For this age group two vaccines – Cadila’s ZyCov-D and Covaxin have approved by the drug regulator and hence positive for Cadila and Hester Biosciences, as it has a tie up with Bharat Biotech for manufacturing Covaxin
  • Hester signs two agreements with ICAR-IVRI

    8 Apr 2021 , 12:36PM Hester Biosciences acquires technology for production of classical swine fever & sheep pox vaccines
  • IIT Guwahati collaborates with Hester Biosciences

    29 Apr 2020 , 11:37AM IIT Guwahati collaborates with Hester Biosciences Limited to develop vaccine against COVID-19
  • Hester Biosciences board to raise fund up to Rs. 150 crore

    18 Dec 2019 , 11:31AM Hester Biosciences board approves raising up to Rs. 150 crore via QIP or preferential allotment
  • Hester Biosciences to invest in African subsidiary

    9 Jun 2017 , 10:56AM Hester Biosciences plans to invest $3 million in its wholly-owned subsidiary in Africa - Hester Biosciences Africa Limited, Tanzania

Key fundamentals

Evaluate the intrinsic value of Hester Biosciences Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 446.276 456.704 390.347 241.967 242.326
Liabilities 446.276 456.704 390.347 241.967 242.326
Equity 8.507 8.507 8.507 8.507 8.507
Gross Profit 47.341 54.886 60.569 71.993 52.721
Net Profit 27.159 32.342 39.517 39.901 31.224
Cash From Operating Activities 42.812 33.362 15.905 40.071 25.822
NPM(%) 9.52 12.73 18.01 19.13 18.42
Revenue 285.155 254 219.351 208.477 169.425
Expenses 237.814 199.114 158.782 136.484 116.704
ROE(%) 8.99 10.71 13.09 13.21 10.34

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
22 Aug 2024 6 60 0.44 1735.8
13 Sep 2023 8 80 0.44 1723.7
11 Aug 2022 10 100 0.44 2276.75
05 Aug 2021 10 100 0.44 2754.9
27 Aug 2020 6.6 66 0.44 1254
18 Jul 2019 7 70 0.44 1531.15
09 Nov 2018 2 20 0.44 1156.35
30 Aug 2018 2 20 0.44 1345.85
02 Aug 2018 6 60 0.44 1529.6
20 Jul 2017 2.3 23 0.44 879.2
03 Nov 2016 3 30 0.44 756.75
21 Jul 2016 1.1 11 0.44 648.05
17 Mar 2016 3 30 0.44 425.45
10 Sep 2015 3.1 31 0.44 548.4

Peers

Other companies within the same industry or sector that are comparable to Hester Biosciences Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 808.20 -1.14 11.41 769.87 1321.50 1.42
Lotus Eye Hospital and Institute Ltd 57.06 -0.77 237.75 2805.32 14.01 0.88
Vaishali Pharma Ltd 12.12 -5.90 606.00 1445.97 2.31 0.00
Astec Lifesciences Ltd 653.90 -5.55 0.00 2645.17 -239.30 0.00

Company Info

YEAR EVENTS 1987 - The Company was incorporated in 29th April as a Private Limited Company. It was subsequently coverted into a Public Limited Company on 1st November 1993. - Hester Pharmaceuticals Limited is an existing porfit amking company engaged in the business of marketing and distribution of veterinary and pharmaceutical products viz, Animal Health prdoducts, Poultry Vaccines, Poultry Diagnostic, Laboratory Kits and Reagents. - HPL represents many international companies for marketing veterinary products. Some of these companies are GHEN CORPORATION, JAPAN for animal and agro based products, MARINE BIOLOGICAL LABORATORIES, USA for poultry vaccines, IDEXX CORPORATION, USA for Laboratory Kits & Reagents, INTERNATIONAL DIAGNOSTIC SYSTEMS CORPORATION, USA for animal kits for detection of drug abuse, BIOGALGALTED LABORATORIES, ISRAEL for Poultry Diagnostic Kits and KEMIN EUROPA, BELGIUM for feed Additives and Disinfectants. - The Company has been promoted by Mr. Rajiv D. Gandhi, his brother Mr. Sanjiv D. Gandhi and Dr. Bhupendra V. Gandhi. 1994 - The company came out with a Public Issue of 21,40,000 No. of equity shares of Rs. 10/- each for cash at par aggregating, Rs. 214.00 lacs on the 17th August to part finance the company's project to manufacture poultry vaccines, to enlist the shares of the company on the stock exchanges at Ahmedabad, Bombay and to meet the expenses of the Issue. 1997 - The company has created an excellent manufacturing facility to produce Animal Vaccines. 1999 - Mr. Vinod Agarwala, Director, resigned from the Board, due to personal reasons. Mr. A.C. Patel was appointed as a Nominee Director of Gujarat Industrial Investment Corporation Limited in place of Mr. C.R. Damani. Mr. Ravin Gandhi and Ms. Bela Gandhi have been appointed as additional Directors in the Company. 2000 - Ahmedabad-based Hester Pharmaceuticals Ltd. an Indo-american joint venture company manufacturing the largest range of poultry vaccines in India has entered into a contract manufacturing agreement with the Tokyo-based Sinsui Inc. 2004 - delisted from Ahmedabad Stock Exchange wef October 15, 2004. 2008 - Company name has been changed from Hester Pharmaceuticals Ltd to Hester Biosciences Ltd. -Hester Biosciences Ltd Issues Rights in the Ratio of 2:5 2010 - Hester Biosciences Ltd has appointed Mr. Vishvesh Patel as a Non-Executive Independent Director of the Company, w.e.f. May 23, 2010, by the Board of Directors of the Company in their meeting held on May 23, 2010. 2011 -Hester Biosciences has recommended a Dividend of Rs. 3.50 per equity share of Rs. 10 each (35%) 2012 -Hester entered into a Business Transfer Agreement (BTA) with Innoves Animal Health Private Limited, a Delhi based company involved in the marketing of Large Animal Health Products for the dairy -Hester Biosciences has given the Bonus in the Ratio of 1:2 2013 -Hester Biosciences L - WHO GMP Certification awarded to Hester Launching of Bivalent Marek's Disease Live Vaccine containing 2014 -Hester Biosciences board approves scheme of amalgamation -The Company has recommended a dividend of Rs. 2.00 per equity share of Rs. 10 each (20%) for the financial year 2013-14 2015 - "Hester Biosciences launches PPR vaccine and Goat Pox vaccine". 2020 - launch of the thermo-tolerant PPR Vaccine by Hester Nepal". 2021 - Hester to produce and commercialize Classical Swine Fever Vaccine and Sheep Pox Vaccine

YEAR EVENTS 1987 - The Company was incorporated in 29th April as a Private Limited Company. It was subsequently coverted into a Public Limited Company on 1st November 1993. - Hester Pharmaceuticals Limited is an existing porfit amking company engaged in the business of marketing and distribution of veterinary and pharmaceutical products viz, Animal Health prdoducts, Poultry Vaccines, Poultry Diagnostic, Laboratory Kits and Reagents. - HPL represents many international companies for marketing veterinary products. Some of these companies are GHEN CORPORATION, JAPAN for animal and agro based products, MARINE BIOLOGICAL LABORATORIES, USA for poultry vaccines, IDEXX CORPORATION, USA for Laboratory Kits & Reagents, INTERNATIONAL DIAGNOSTIC SYSTEMS CORPORATION, USA for animal kits for detection of drug abuse, BIOGALGALTED LABORATORIES, ISRAEL for Poultry Diagnostic Kits and KEMIN EUROPA, BELGIUM for feed Additives and Disinfectants. - The Company has been promoted by Mr. Rajiv D. Gandhi, his brother Mr. Sanjiv D. Gandhi and Dr. Bhupendra V. Gandhi. 1994 - The company came out with a Public Issue of 21,40,000 No. of equity shares of Rs. 10/- each for cash at par aggregating, Rs. 214.00 lacs on the 17th August to part finance the company's project to manufacture poultry vaccines, to enlist the shares of the company on the stock exchanges at Ahmedabad, Bombay and to meet the expenses of the Issue. 1997 - The company has created an excellent manufacturing facility to produce Animal Vaccines. 1999 - Mr. Vinod Agarwala, Director, resigned from the Board, due to personal reasons. Mr. A.C. Patel was appointed as a Nominee Director of Gujarat Industrial Investment Corporation Limited in place of Mr. C.R. Damani. Mr. Ravin Gandhi and Ms. Bela Gandhi have been appointed as additional Directors in the Company. 2000 - Ahmedabad-based Hester Pharmaceuticals Ltd. an Indo-american joint venture company manufacturing the largest range of poultry vaccines in India has entered into a contract manufacturing agreement with the Tokyo-based Sinsui Inc. 2004 - delisted from Ahmedabad Stock Exchange wef October 15, 2004. 2008 - Company name has been changed from Hester Pharmaceuticals Ltd to Hester Biosciences Ltd. -Hester Biosciences Ltd Issues Rights in the Ratio of 2:5 2010 - Hester Biosciences Ltd has appointed Mr. Vishvesh Patel as a Non-Executive Independent Director of the Company, w.e.f. May 23, 2010, by the Board of Directors of the Company in their meeting held on May 23, 2010. 2011 -Hester Biosciences has recommended a Dividend of Rs. 3.50 per equity share of Rs. 10 each (35%) 2012 -Hester entered into a Business Transfer Agreement (BTA) with Innoves Animal Health Private Limited, a Delhi based company involved in the marketing of Large Animal Health Products for the dairy -Hester Biosciences has given the Bonus in the Ratio of 1:2 2013 -Hester Biosciences L - WHO GMP Certification awarded to Hester Launching of Bivalent Marek's Disease Live Vaccine containing 2014 -Hester Biosciences board approves scheme of amalgamation -The Company has recommended a dividend of Rs. 2.00 per equity share of Rs. 10 each (20%) for the financial year 2013-14 2015 - "Hester Biosciences launches PPR vaccine and Goat Pox vaccine". 2020 - launch of the thermo-tolerant PPR Vaccine by Hester Nepal". 2021 - Hester to produce and commercialize Classical Swine Fever Vaccine and Sheep Pox Vaccine

Read More

Parent Organisation

Hester Biosciences Ltd.

Founded

29/04/1987

Managing Director

Mr.Rajiv Gandhi

NSE Symbol

HESTERBIOEQ

FAQ

The current price of Hester Biosciences Ltd is ₹ 1352.40.

The 52-week high for Hester Biosciences Ltd is ₹ 1378.25 and the 52-week low is ₹ 1275.00.

The market capitalization of Hester Biosciences Ltd is currently ₹ 1150.47. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Hester Biosciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Hester Biosciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Hester Biosciences Ltd shares.

The CEO of Hester Biosciences Ltd is Mr.Rajiv Gandhi, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT